Jake Chervinsky, CEO of the Hyperliquid Policy Center, has criticized the CME Group's lawsuit against the U.S. Commodity Futures Trading Commission (CFTC), calling it a "shocking misjudgment" and an "unnecessary misstep." Chervinsky argues that the CME Group, which dominates 92% of the U.S. derivatives market, is acting as a "monopolistic vested interest" fearful of competition.
The lawsuit comes as U.S. regulators have recently opened a compliance pathway for perpetual contracts, a move that could increase market choice and reduce costs for U.S. users who have historically turned to overseas markets for such products. Chervinsky highlights that the CME's legal action aims to "shut down this channel," potentially stifling competition and innovation in the derivatives market.
Hyperliquid CEO Criticizes CME's Lawsuit Against CFTC as Anti-Competitive
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.
